Table 2.
Tumour responses
| Anti-PD-1-exposed group | Anti-PD-1-naive group | P value | |
| Overall population | n=56 | n=138 | |
| CR | 0 | 0 | |
| PR | 25 (45.5%) | 27 (19.6%) | |
| SD | 20 (35.7%) | 68 (49.3%) | |
| PD | 10 (17.9%) | 43 (31.2%) | |
| NE | 1 (1.8%) | 0 (0.0%) | |
| ORR (%) | 44.6 | 19.6 | 0.001 |
| DCR (%) | 80.6 | 68.8 | 0.12 |
| Taxanes+RAM | n=33 | n=85 | |
| CR | 0 | 0 | |
| PR | 20 (60.6%) | 17 (20.0%) | |
| SD | 9 (27.3%) | 40 (47.1%) | |
| PD | 4 (12.1%) | 28 (32.9%) | |
| ORR (%) | 60.6 | 20.0 | <0.001 |
| DCR (%) | 87.9 | 67.1 | 0.023 |
| Taxanes | n=9 | n=17 | |
| CR | 0 | 0 | |
| PR | 2 (22.2%) | 4 (23.5%) | |
| SD | 4 (44.4%) | 9 (52.9%) | |
| PD | 2 (22.2%) | 4 (23.5%) | |
| NE | 1 (11.1%) | 0 (0.0%) | |
| ORR (%) | 22.2 | 23.5 | 1.00 |
| DCR (%) | 66.7 | 76.5 | 0.66 |
| Irinotecan | n=14 | n=36 | |
| CR | 0 | 0 | |
| PR | 3 (21.4%) | 6 (16.7%) | |
| SD | 6 (42.9%) | 13 (36.1%) | |
| PD | 5 (35.7%) | 17 (47.2%) | |
| ORR (%) | 21.4 | 16.7 | 0.70 |
| DCR (%) | 64.2 | 52.8 | 0.54 |
CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; RAM, ramucirumab; SD, stable disease.